Terns Pharmaceuticals Ownership
| TERN Stock | USD 3.35 0.21 6.69% |
Shares in Circulation | First Issued 2019-12-31 | Previous Quarter 77.8 M | Current Value 84.9 M | Avarage Shares Outstanding 44.9 M | Quarterly Volatility 25.3 M |
Terns |
Terns Stock Ownership Analysis
About 100.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.83. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Terns Pharmaceuticals recorded a loss per share of 1.12. The entity had not issued any dividends in recent years. The firm had 1000:50 split on the 4th of November 2013. Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. Terns Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people. To find out more about Terns Pharmaceuticals contact Senthil Sundaram at 650 525 5535 or learn more at https://www.ternspharma.com.Besides selling stocks to institutional investors, Terns Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Terns Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Terns Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Terns Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Terns Pharmaceuticals Insider Trades History
Less than 1% of Terns Pharmaceuticals are currently held by insiders. Unlike Terns Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Terns Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Terns Pharmaceuticals' insider trades
Terns Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Terns Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Terns Pharmaceuticals backward and forwards among themselves. Terns Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Terns Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Superstring Capital Management Lp | 2024-12-31 | 2 M | Driehaus Capital Management Llc | 2024-12-31 | 1.7 M | Millennium Management Llc | 2024-12-31 | 1.6 M | Geode Capital Management, Llc | 2024-12-31 | 1.5 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 1.5 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.3 M | State Street Corp | 2024-12-31 | 1.3 M | Point72 Asset Management, L.p. | 2024-12-31 | 1.3 M | Vr Adviser, Llc | 2024-12-31 | 1.1 M | Soleus Capital Management, L.p. | 2024-12-31 | 8.1 M | Orbimed Advisors, Llc | 2024-12-31 | 7.6 M |
Terns Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Terns Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Terns Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Terns Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Terns Pharmaceuticals Outstanding Bonds
Terns Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Terns Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Terns bonds can be classified according to their maturity, which is the date when Terns Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Terns Pharmaceuticals Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 25th of February 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 3rd of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Pair Trading with Terns Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Terns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Terns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Terns Stock
| 0.84 | CDIOW | Cardio Diagnostics | PairCorr |
| 0.87 | VINC | Vincerx Pharma Earnings Call This Week | PairCorr |
| 0.85 | ELVN | Enliven Therapeutics | PairCorr |
Moving against Terns Stock
| 0.91 | SNY | Sanofi ADR | PairCorr |
| 0.87 | AZN | AstraZeneca PLC ADR | PairCorr |
| 0.8 | GILD | Gilead Sciences | PairCorr |
| 0.75 | GOSS | Gossamer Bio | PairCorr |
| 0.69 | PLX | Protalix Biotherapeutics | PairCorr |
The ability to find closely correlated positions to Terns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Terns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Terns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Terns Pharmaceuticals to buy it.
The correlation of Terns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Terns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Terns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Terns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Terns Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Terns Stock, please use our How to Invest in Terns Pharmaceuticals guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Terns Pharmaceuticals. If investors know Terns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Terns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Terns Pharmaceuticals is measured differently than its book value, which is the value of Terns that is recorded on the company's balance sheet. Investors also form their own opinion of Terns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Terns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Terns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Terns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Terns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Terns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Terns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.